This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"For a number of reasons, my top stock pick for 2011 is Affymetrix (AFFX)," says biotech sector specialist Nate Pile.

The editor of Nate's Notes explains, "This small company based in Santa Clara, CA, develops, manufactures, sells, and services equipment and consumables used in the life sciences industry to do what is know as 'high throughput genetic screening.'

Continue reading Top Picks 2011: Affymetrix (AFFX)

Top Picks 2011: Affymetrix (AFFX) originally appeared on BloggingStocks on Fri, 07 Jan 2011 15:00:00 EST. Please see our terms for use of feeds.

"Two of our long-standing buy recommendations are involved in selling products and services for the genetic research market: Affymetrix (AFFX) and Illumina (ILMN)," notes biotech and growth stock specialist Nate Pile.

The editor of Nate's Notes explains, "In a nutshell, both of these companies have developed technologies that allow researchers to do what is known as 'high-throughput genetic screening'.

"And, while the two companies are direct competitors in many of the markets in which they compete, we believe that both stocks should be bought at the current time.

Continue reading Genetic Gains? Affymetrix (AFFX) and Illumina (ILMN)

Genetic Gains? Affymetrix (AFFX) and Illumina (ILMN) originally appeared on BloggingStocks on Tue, 21 Sep 2010 10:20:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"My top stock pick for 2010 is MannKind Corp. (MNKD), which is developing a a novel formulation of inhalable insulin called Afresa," notes Nate Pile.

In his Nate's Notes newsletter, he explains, "I would emphasize that while the stock must be considered speculative until the FDA delivers a ruling in mid-January of next year, I believe the clinical data that has been submitted by the company is likely to warrant approval."

Continue reading Top Picks for 2010: MannKind (MNKD)

Top Picks for 2010: MannKind (MNKD) originally appeared on BloggingStocks on Tue, 05 Jan 2010 14:00:00 EST. Please see our terms for use of feeds.

"In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile.

In his growth-oriented Nate's Notes, the advisor cautions, "I believe we are looking at a situation in which we will either lose most of our money, or triple (or better) our investment in a fairly short period of time."

"In a nutshell, the company's near-term fate hinges upon AFRESA, a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia.

"Working against the company is the fact that there has never been an inhaled insulin product approved for commercial use that has worked very well.

Continue reading MannKind: Speculation on inhaled insulin

MannKind: Speculation on inhaled insulin originally appeared on BloggingStocks on Mon, 06 Jul 2009 15:40:00 EST. Please see our terms for use of feeds.

"Everyone who wants out has probably already done their selling," says Nate Pile, who sees a "sidways to up' market. In his Nate's Notes, the advisor sees opportunity in a trio of techs.

"My experience with market cycles continues to suggest to me that the odds favor a 'sideways or up' market over the next several months.

"Meanwhile, Apple (NASDAQ: AAPL) is technically still stuck in a trading range, I am very pleased with the leadership it has shown in the market over the past several weeks.

Continue reading Tech trio: AAPL, ERTS & NVDA

Tech trio: AAPL, ERTS & NVDA originally appeared on BloggingStocks on Thu, 12 Mar 2009 11:20:00 EST. Please see our terms for use of feeds.

"While I've watched video game maker Electronic Arts (NASDAQ: ERTS) for many years, I've never felt it was cheap," says growth stock specialist Nate Pile.

In his Nate's Notes, he now says, "I am thrilled to see the stock price finally experience the sort of pullback that justifies a buy rating; indeed, I wasn't interested at $50 four months ago, but at $17 today, I can't help but get excited."

"Over the years, Electronic Arts has amassed an impressive library of titles. In particular, you may be familiar with the entire Sims collection, as well as the company's extensive lineup of sports games (including Madden NFL and Tiger Woods PGA Tour, for example).

"In addition, Spore is a recently introduced hit, and some other titles you may be familiar with (or at least seen in TV commercials) include Need For Speed, Medal of Honor, and Rock Band.

Continue reading Electronic Arts (EA): A value in video gaming?

Electronic Arts (EA): A value in video gaming? originally appeared on BloggingStocks on Wed, 28 Jan 2009 13:15:00 EST. Please see our terms for use of feeds.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"We believe that the most prudent way to make money in the stock market is through long-term investing in 'best of the best' companies," says growth stock specialist Nate Pile.

In his Nate's Notes newsletter, he explains, "With that in mind, we turn to one of our core portfolio holdings as out favorite investment for 2009 -- Apple (NASDAQ: AAPL), whose products represent 'best in class' in just about every category in which it competes.

"We believe investors have shifted their focus entirely to the extreme near-term and are completely ignoring the long-term fundamentals that are in place for the Apple.

"To be sure, the stock has lost over 50% of its value over the past twelve months, but we believe the reasons for the decline are all short-term in nature, and we cannot help but get excited by the opportunity to once again become more aggressive about adding additional shares to our portfolio.

Continue reading Top Stock Picks '09: Apple (AAPL)

Top Stock Picks '09: Apple (AAPL) originally appeared on BloggingStocks on Thu, 01 Jan 2009 12:30:00 EST. Please see our terms for use of feeds.

Two leading advisors with noted expertise in the biotech sector have both been long-term fans of Celgene (NASDAQ: CELG), both holding the stock in their respective model portfolios.

Here, Nate Pile, editor of Nate's Notes, and John McCamant, editor of The Medical Technology Stock Letter, each take a look at the encouraging prospects for this biotechnology firm.

Nate Pile explains, "Now that the Pharmion merger is behind us, it appears that investors are once again
recognizing Celgene for what it is - namely, one of the premier stories in the biopharmaceutical space.

"As I have said a number of times before, if I could only own one biotech stock for the next ten years, Celgene would be it... and I encourage you to make it a 'first choice' for your portfolio as well!

"The stock is likely to exhibit its usual volatility around the company's upcoming earnings report, but I encourage you to take advantage of any sell-off that may occur to aggressively add to your position in this market leader. CELG is now considered a strong buy under $60 and a buy under $68."

John McCamant states, "Celgene had some good news of late on the thalidomide front. The company has received approval of the application to expand the drug's label to treat newly diagnosed multiple myeloma (MM) patients in Australia.

Continue reading Biotech experts bet on Celgene (CELG)

Biotech experts bet on Celgene (CELG) originally appeared on BloggingStocks on Mon, 05 May 2008 11:35:00 EST. Please see our terms for use of feeds.